Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Disease
1.1.2. End-use
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease outlook
2.2.2. End-use outlook
2.3. Competitive Insights
Chapter 3. U.S. Molecular Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.1.1. Increase in geriatric population
3.4.1.2. Introduction of technologically advanced products
3.4.1.3. Increase in demand for point-of-care testing
3.4.1.4. Growing prevalence of target diseases
3.4.1.5. Increasing external funding for R&D
3.4.2. Market Restraint Analysis
3.4.2.1. Presence of Ambiguous Regulatory Framework
3.4.2.2. High prices of molecular diagnostics tests
3.5. U.S. Molecular Diagnostics Market Analysis Tools
3.5.1. Industry Analysis - Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic Landscape
3.5.3. Major Deals & Strategic Alliances Analysis
3.5.4. Market Entry Strategies
Chapter 4. U.S. Molecular Diagnostics Market: Disease Estimates & Trend Analysis
4.1. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.1.1. Healthcare-Associated Infections
4.1.1.1. Methicillin-Resistant Staphylococcus aureus
4.1.1.1.1. Methicillin-Resistant Staphylococcus aureus Market Estimates and forecast 2018 to 2030 (USD Million)
4.1.1.2. Staphylococcus aureus
4.1.1.2.1. Staphylococcus aureus Market Estimates and forecast 2018 to 2030 (USD Million)
4.1.1.3. Enterovirus
4.1.1.3.1. Enterovirus market estimates and forecast 2018 to 2030 (USD Million)
4.1.1.4. Clostridioides difficile
4.1.1.4.1. Clostridioides difficile market estimates and forecast 2018 to 2030 (USD Million)
4.1.1.5. Van A
4.1.1.5.1. Van A market estimates and forecast 2018 to 2030 (USD Million)
4.1.1.6. Sepsis Panel
4.1.1.6.1. Sepsis Panel market estimates and forecast 2018 to 2030 (USD Million)
4.1.2. Respiratory
4.1.2.1. Flu
4.1.2.1.1. Flu market estimates and forecast 2018 to 2030 (USD Million)
4.1.2.2. Respiratory Syncytial Virus
4.1.2.2.1. Respiratory Syncytial Virus market estimates and forecast 2018 to 2030 (USD Million)
4.1.2.3. Paraflu
4.1.2.3.1. Paraflu market estimates and forecast 2018 to 2030 (USD Million)
4.1.2.4. Multidrug-Resistant Tuberculosis
4.1.2.4.1. Multidrug-Resistant Tuberculosis market estimates and forecast 2018 to 2030 (USD Million)
4.1.2.5. Mycobacterium Avium-Intracellular
4.1.2.5.1. Mycobacterium Avium-Intracellulare market estimates and forecast 2018 to 2030 (USD Million)
4.1.2.6. Group A Streptococcal
4.1.2.6.1. Group A Streptococcal market estimates and forecast 2018 to 2030 (USD Million)
4.1.2.7. Adenovirus
4.1.2.7.1. Adenovirus market estimates and forecast 2018 to 2030 (USD Million)
4.1.2.8. Human Metapneumovirus
4.1.2.8.1. Human Metapneumovirus market estimates and forecast 2018 to 2030 (USD Million)
4.1.2.9. Rhinoviruses
4.1.2.9.1. Rhinoviruses market estimates and forecast 2018 to 2030 (USD Million)
4.1.2.10. Middle East Respiratory Syndrome Coronavirus
4.1.2.10.1. Middle East Respiratory Syndrome Coronavirus market estimates and forecast 2018 to 2030 (USD Million)
4.1.2.11. Tuberculosis
4.1.2.11.1. Tuberculosis market estimates and forecast 2018 to 2030 (USD Million)
4.1.2.12. Severe Acute Respiratory Syndrome Coronavirus 2
4.1.2.12.1. Severe Acute Respiratory Syndrome Coronavirus 2 market estimates and forecast 2018 to 2030 (USD Million)
4.1.2.13. Human Bocavirus-Infection
4.1.2.13.1. Human Bocavirus-Infection market estimates and forecast 2018 to 2030 (USD Million)
4.1.2.14. Bordetella
4.1.2.14.1. Bordetella market estimates and forecast 2018 to 2030 (USD Million)
4.1.2.15. Mycoplasma Pneumonia
4.1.2.15.1. Mycoplasma Pneumonia market estimates and forecast 2018 to 2030 (USD Million)
4.1.2.16. Respiratory Panels
4.1.2.16.1. Respiratory Panels market estimates and forecast 2018 to 2030 (USD Million)
4.1.3. Gastrointestinal
4.1.3.1. Norovirus
4.1.3.1.1. Norovirus market estimates and forecast 2018 to 2030 (USD Million)
4.1.3.2. Helicobacter pylori
4.1.3.2.1. Helicobacter pylori market estimates and forecast 2018 to 2030 (USD Million)
4.1.3.3. Shiga toxin
4.1.3.3.1. Shiga toxin Market Estimates and forecast 2018 to 2030 (USD Million)
4.1.3.4. GI Parasite Panel
4.1.3.4.1. GI Parasite Panel market estimates and forecast 2018 to 2030 (USD Million)
4.1.3.5. GI Bacterial Panel
4.1.3.5.1. GI Bacterial Panel market estimates and forecast 2018 to 2030 (USD Million)
4.1.3.6. GI Viral Panel
4.1.3.6.1. GI Viral Panel market estimates and forecast 2018 to 2030 (USD Million)
4.1.3.7. GI Panels
4.1.3.7.1. GI Panels market estimates and forecast 2018 to 2030 (USD Million)
4.1.4. Women’s Health/STI
4.1.4.1. Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG)
4.1.4.1.1. Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) market estimates and forecast 2018 to 2030 (USD Million)
4.1.4.2. Trichomonas Vaginalis
4.1.4.2.1. Trichomonas Vaginalis market estimates and forecast 2018 to 2030 (USD Million)
4.1.4.3. Mycoplasma Genitalium
4.1.4.3.1. Mycoplasma genitalium market estimates and forecast 2018 to 2030 (USD Million)
4.1.4.4. Human Papillomavirus
4.1.4.4.1. Human Papillomavirus market estimates and forecast 2018 to 2030 (USD Million)
4.1.4.5. Bacterial Vaginosis
4.1.4.5.1. Bacterial Vaginosis market estimates and forecast 2018 to 2030 (USD Million)
4.1.4.6. Gonorrhoea Colloquially
4.1.4.6.1. Gonorrhoea Colloquially market estimates and forecast 2018 to 2030 (USD Million)
4.1.4.7. Mycoplasma Genitalium Resistance
4.1.4.7.1. Mycoplasma Genitalium Resistance market estimates and forecast 2018 to 2030 (USD Million)
4.1.4.8. Herpes Simplex Virus
4.1.4.8.1. Herpes Simplex Virus market estimates and forecast 2018 to 2030 (USD Million)
4.1.4.9. Group B Streptococcus
4.1.4.9.1. Group B Streptococcus market estimates and forecast 2018 to 2030 (USD Million)
4.1.5. Immunocompromised
4.1.5.1. Cytomegalovirus
4.1.5.1.1. Cytomegalovirus market estimates and forecast 2018 to 2030 (USD Million)
4.1.5.2. Epstein-Barr virus
4.1.5.2.1. Epstein-Barr virus market estimates and forecast 2018 to 2030 (USD Million)
4.1.5.3. Varicella-Zoster Virus
4.1.5.3.1. Varicella-Zoster Virus market estimates and forecast 2018 to 2030 (USD Million)
4.1.5.4. BK virus
4.1.5.4.1. BK virus market estimates and forecast 2018 to 2030 (USD Million)
4.1.6. Virology
4.1.6.1. Human immunodeficiency viruses
4.1.6.1.1. Human immunodeficiency viruses market estimates and forecast 2018 to 2030 (USD Million)
4.1.6.2. Hepatitis C virus
4.1.6.2.1. Hepatitis C virus market estimates and forecast 2018 to 2030 (USD Million)
4.1.6.3. Hepatitis B virus
4.1.6.3.1. Hepatitis B virus Market Estimates and forecast 2018 to 2030 (USD Million)
4.1.6.4. Hepatitis E virus
4.1.6.4.1. Hepatitis E virus market estimates and forecast 2018 to 2030 (USD Million)
4.1.7. Other Targets
4.1.7.1. Babesia
4.1.7.1.1. Babesia market estimates and forecast 2018 to 2030 (USD Million)
4.1.7.2. Zika
4.1.7.2.1. Zika market estimates and forecast 2018 to 2030 (USD Million)
4.1.7.3. West Nile Virus
4.1.7.3.1. West Nile Virus market estimates and forecast 2018 to 2030 (USD Million)
4.1.7.4. Chikungunya virus/Dengue virus
4.1.7.4.1. Chikungunya virus/Dengue Virus Market Estimates and forecast 2018 to 2030 (USD Million)
4.1.7.5. Enhancer of zeste homolog 2
4.1.7.5.1. Enhancer of zeste homolog 2 market estimates and forecast 2018 to 2030 (USD Million)
4.1.7.6. PIK3CA
4.1.7.6.1. PIK3CA market estimates and forecast 2018 to 2030 (USD Million)
4.1.7.7. Malaria
4.1.7.7.1. Malaria market estimates and forecast 2018 to 2030 (USD Million)
4.1.7.8. Monkeypox Virus
4.1.7.8.1. Monkeypox Virus market estimates and forecast 2018 to 2030 (USD Million)
4.1.8. Other Panels
4.1.8.1. Meningitis Panel
4.1.8.1.1. Meningitis Panel market estimates and forecast 2018 to 2030 (USD Million)
4.1.8.2. Lyme Panel
4.1.8.2.1. Lyme Panel market estimates and forecast 2018 to 2030 (USD Million)
4.1.8.3. UTI Panel
4.1.8.3.1. UTI Panel market estimates and forecast 2018 to 2030 (USD Million)
4.1.9. Oncology
4.1.9.1. Microsatellite Instability
4.1.9.1.1. Microsatellite Instability market estimates and forecast 2018 to 2030 (USD Million)
4.1.9.2. B-raf
4.1.9.2.1. B-raf market estimates and forecast 2018 to 2030 (USD Million)
4.1.9.3. Epidermal Growth Factor Receptor
4.1.9.3.1. Epidermal Growth Factor Receptor market estimates and forecast 2018 to 2030 (USD Million)
4.1.9.4. Kirsten Rat Sarcoma Virus
4.1.9.4.1. Kirsten Rat Sarcoma Virus market estimates and forecast 2018 to 2030 (USD Million)
4.1.9.5. Others
4.1.9.5.1. Others Market Estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. U.S. Molecular Diagnostics Market: End-use Estimates & Trend Analysis
5.1. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.1.1. Hospital Core Laboratory
5.1.1.1. Hospital Core Laboratory market estimates and forecast 2018 to 2030 (USD Million)
5.1.2. Hospital Alternative Sites
5.1.2.1. Hospital Alternative Sites market estimates and forecast 2018 to 2030 (USD Million)
5.1.3. Decentralized Test Sites
5.1.3.1. Decentralized Test Site market estimates and forecast 2018 to 2030 (USD Million)
5.1.4. Reference Lab
5.1.4.1. Reference Lab market Estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company/Competition Categorization
6.3. Vendor Landscape
6.3.1. List of key distributors and channel partners
6.3.2. Key customers
6.3.3. Key Company Market Share Analysis, 2022
6.3.4. Abbott
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Product benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Siemens Healthcare GmbH
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Product benchmarking
6.3.5.4. Strategic initiatives
6.3.6. QIAGEN
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Product benchmarking
6.3.6.4. Strategic initiatives
6.3.7. F. Hoffmann-La Roche Ltd
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Product benchmarking
6.3.7.4. Strategic initiatives
6.3.8. Quest Diagnostics Incorporated
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Product benchmarking
6.3.8.4. Strategic initiatives
6.3.9. Danaher
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Product benchmarking
6.3.9.4. Strategic initiatives
6.3.10. Thermo Fisher Scientific, Inc.
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Product benchmarking
6.3.10.4. Strategic initiatives
6.3.11. Hologic Inc.
6.3.11.1. Company overview
6.3.11.2. Financial performance
6.3.11.3. Product benchmarking
6.3.11.4. Strategic initiatives
6.3.12. BD
6.3.12.1. Company overview
6.3.12.2. Financial performance
6.3.12.3. Product benchmarking
6.3.12.4. Strategic initiatives
6.3.13. Charles River Laboratories
6.3.13.1. Company overview
6.3.13.2. Financial performance
6.3.13.3. Product benchmarking
6.3.13.4. Strategic initiatives
6.3.14. Bio-Rad Laboratories, Inc.
6.3.14.1. Company overview
6.3.14.2. Financial performance
6.3.14.3. Product benchmarking
6.3.14.4. Strategic initiatives
6.3.15. Illumina, Inc.
6.3.15.1. Company Overview
6.3.15.2. Financial performance
6.3.15.3. Product benchmarking
6.3.15.4. Strategic initiatives
6.3.16. Agilent Technologies, Inc.
6.3.16.1. Company Overview
6.3.16.2. Financial performance
6.3.16.3. Product benchmarking
6.3.16.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 List of Secondary Sources
Table 3 U.S. Molecular Diagnostics Market, by Disease, 2018 - 2030 (USD Million)
Table 4 U.S. Molecular Diagnostics Market, by End Use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. molecular diagnostics market: market outlook
Fig. 9 U.S. Molecular Diagnostics Market Competitive Insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 U.S. molecular diagnostics market driver impact
Fig. 15 U.S. molecular diagnostics market restraint impact
Fig. 16 U.S. Molecular Diagnostics Market Strategic Initiatives Analysis
Fig. 17 U.S. molecular diagnostics market: disease movement analysis
Fig. 18 U.S. molecular diagnostics market: disease outlook and key takeaways
Fig. 19 Methicillin-Resistant Staphylococcus aureus market estimates and forecast, 2018 - 2030
Fig. 20 Staphylococcus aureus market estimates and forecast, 2018 - 2030
Fig. 21 Enterovirus market estimates and forecast, 2018 - 2030
Fig. 22 Clostridioides difficile market estimates and forecast, 2018 - 2030
Fig. 23 Van A market estimates and forecast, 2018 - 2030
Fig. 24 Sepsis Panel market estimates and forecast, 2018 - 2030
Fig. 25 Flu market estimates and forecast, 2018 - 2030
Fig. 26 Respiratory Syncytial Virus market estimates and forecast, 2018 - 2030
Fig. 27 Paraflu market estimates and forecast, 2018 - 2030
Fig. 28 Multidrug-Resistant Tuberculosis market estimates and forecast, 2018 - 2030
Fig. 29 Mycobacterium Avium-Intracellulare market estimates and forecast, 2018 - 2030
Fig. 30 Group A Streptococcal market estimates and forecast, 2018 - 2030
Fig. 31 Adenovirus market estimates and forecast, 2018 - 2030
Fig. 32 Human Metapneumovirus market estimates and forecast, 2018 - 2030
Fig. 33 Rhinoviruses market estimates and forecast, 2018 - 2030
Fig. 34 Middle East Respiratory Syndrome Coronavirus market estimates and forecast, 2018 - 2030
Fig. 35 Tuberculosis market estimates and forecast, 2018 - 2030
Fig. 36 Severe Acute Respiratory Syndrome Coronavirus 2 market estimates and forecast, 2018 - 2030
Fig. 37 Human Bocavirus-Infection market estimates and forecast, 2018 - 2030
Fig. 38 Bordetella market estimates and forecast, 2018 - 2030
Fig. 39 Mycoplasma Pneumonia market estimates and forecast, 2018 - 2030
Fig. 40 Respiratory Panels market estimates and forecast, 2018 - 2030
Fig. 41 Norovirus market estimates and forecast, 2018 - 2030
Fig. 42 Helicobacter pylori market estimates and forecast, 2018 - 2030
Fig. 43 Shiga toxin market estimates and forecast, 2018 - 2030
Fig. 44 GI Parasite Panel market estimates and forecast, 2018 - 2030
Fig. 45 GI Bacterial Panel market estimates and forecast, 2018 - 2030
Fig. 46 GI Viral Panel market estimates and forecast, 2018 - 2030
Fig. 47 GI Panels market estimates and forecast, 2018 - 2030
Fig. 48 Women’s Health/STI market estimates and forecast, 2018 - 2030
Fig. 49 Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) market estimates and forecast, 2018 - 2030
Fig. 50 Trichomonas Vaginalis market estimates and forecast, 2018 - 2030
Fig. 51 Mycoplasma Genitalium market estimates and forecast, 2018 - 2030
Fig. 52 Human Papillomavirus market estimates and forecast, 2018 - 2030
Fig. 53 Bacterial Vaginosis market estimates and forecast, 2018 - 2030
Fig. 54 Gonorrhoea Colloquially market estimates and forecast, 2018 - 2030
Fig. 55 Mycoplasma Genitalium Resistance market estimates and forecast, 2018 - 2030
Fig. 56 Herpes Simplex Virus market estimates and forecast, 2018 - 2030
Fig. 57 Group B Streptococcus market estimates and forecast, 2018 - 2030
Fig. 58 Cytomegalovirus market estimates and forecast, 2018 - 2030
Fig. 59 Epstein-Barr virus market estimates and forecast, 2018 - 2030
Fig. 60 Varicella-Zoster Virus market estimates and forecast, 2018 - 2030
Fig. 61 BK virus market estimates and forecast, 2018 - 2030
Fig. 62 Human immunodeficiency viruses market estimates and forecast, 2018 - 2030
Fig. 63 Hepatitis C virus market estimates and forecast, 2018 - 2030
Fig. 64 Hepatitis B virus market estimates and forecast, 2018 - 2030
Fig. 65 Hepatitis E virus market estimates and forecast, 2018 - 2030
Fig. 66 Babesia market estimates and forecast, 2018 - 2030
Fig. 67 Zika market estimates and Forecast, 2018 - 2030
Fig. 68 West Nile Virus market estimates and forecast, 2018 - 2030
Fig. 69 Chikungunya virus/dengue virus market estimates and forecast, 2018 - 2030
Fig. 70 Enhancer of zest homolog 2 market estimates and forecast, 2018 - 2030
Fig. 71 PIK3CA market estimates and forecast, 2018 - 2030
Fig. 72 Malaria market estimates and forecast, 2018 - 2030
Fig. 73 Monkeypox Virus market estimates and forecast, 2018 - 2030
Fig. 74 Meningitis Panel market estimates and forecast, 2018 - 2030
Fig. 75 Lyme Panel market estimates and forecast, 2018 - 2030
Fig. 76 UTI Panel market estimates and forecast, 2018 - 2030
Fig. 77 Microsatellite Instability market estimates and forecast, 2018 - 2030
Fig. 78 B-raf market estimates and forecast, 2018 - 2030
Fig. 79 Epidermal Growth Factor Receptor market estimates and forecast, 2018 - 2030
Fig. 80 Kirsten rat sarcoma virus market estimates and forecast, 2018 - 2030
Fig. 81 Other market estimates and forecast, 2018 - 2030
Fig. 82 U.S. molecular diagnostics market: end-use movement analysis
Fig. 83 U.S. molecular diagnostics market: end-use outlook and key takeaways
Fig. 84 Hospital Core Laboratory market estimates and forecast, 2018 - 2030
Fig. 85 Hospital Alternative Sites market estimates and forecast, 2018 - 2030
Fig. 86 Decentralized Test Sites market estimates and forecast, 2018 - 2030
Fig. 87 Reference Lab market estimates and forecast, 2018 - 2030
Fig. 88 Participant categorization- U.S. molecular diagnostics market
Fig. 89 Market share of key market players- U.S. molecular diagnostics market
